Novel and Investigational Therapies in Acute Myeloid Leukemia

Yazan F. Madanat, Aziz Nazha

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Acute myeloid leukemia (AML) is classified into four broad categories in the revised World Health Organization classification for myeloid neoplasms; AML with recurrent genetic abnormalities, AML with myelodysplasia-related changes, therapy-related myeloid neoplasms, and AML not otherwise specified. With better understanding of the disease biology, many novel agents have been developed and are now incorporated in the treatment paradigm for AML. We summarize in this chapter the molecular landscape of AML, novel therapies that have received regulatory approval, as well as selected investigational agents that are in early stages of development (first-in human trials) and focus on those in later stages of development. Each section will emphasize selected investigational agents based on their mechanism of action or targeted pathway.

Original languageEnglish (US)
Title of host publicationHematologic Malignancies
PublisherSpringer Science and Business Media Deutschland GmbH
Pages133-144
Number of pages12
DOIs
StatePublished - 2021
Externally publishedYes

Publication series

NameHematologic Malignancies
ISSN (Print)2197-9766
ISSN (Electronic)2197-9774

Keywords

  • AML
  • Genomics
  • Monoclonal antibodies
  • Myeloid
  • Targeted therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Novel and Investigational Therapies in Acute Myeloid Leukemia'. Together they form a unique fingerprint.

Cite this